Centro Nacional de Investigaciones Oncológicas -ko ikertzaileekin lankidetzan egindako argitalpenak (18)

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features

    Frontiers in Oncology, Vol. 13

2022

  1. BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up

    European Urology

  2. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review

    Therapeutic Advances in Medical Oncology, Vol. 14

  3. Cabozantinib for the treatment of solid tumors: a systematic review

    Therapeutic Advances in Medical Oncology, Vol. 14

  4. Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis

    OncoImmunology, Vol. 11, Núm. 1

  5. Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib

    Cancers, Vol. 14, Núm. 12

  6. Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy

    Journal of Clinical Medicine, Vol. 11, Núm. 3

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

2020

  1. Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy

    Cancers, Vol. 12, Núm. 7, pp. 1-13

2019

  1. CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402

2018

  1. A genetic polymorphism in ctla-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma

    Clinical Cancer Research, Vol. 24, Núm. 10, pp. 2350-2356

2017

  1. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic- and tumor-related biomarkers for response and toxicity

    Urologic Oncology: Seminars and Original Investigations, Vol. 35, Núm. 8, pp. 529.e9-529.e16

  2. Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma

    Pharmacogenetics and Genomics, Vol. 27, Núm. 6, pp. 227-231

  3. Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients

    Oncotarget, Vol. 8, Núm. 1, pp. 1204-1212

2015

  1. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma

    European Journal of Clinical Pharmacology, Vol. 71, Núm. 12, pp. 1477-1484

  2. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors

    Molecular Carcinogenesis, Vol. 54, Núm. 7, pp. 566-576

  3. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993